Insider Transactions in Q3 2023 at Regeneron Pharmaceuticals, Inc. (REGN)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 08
2023
|
David P Schenkein Director |
BUY
Grant, award, or other acquisition
|
Direct |
240
+50.0%
|
-
|
|
Sep 08
2023
|
Kathryn Guarini Director |
BUY
Grant, award, or other acquisition
|
Direct |
240
+50.0%
|
-
|
|
Sep 01
2023
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
250
-1.25%
|
$208,500
$834.55 P/Share
|
|
Aug 24
2023
|
Daniel P Van Plew EVP & General Mgr, Industrial |
SELL
Open market or private sale
|
Direct |
6,197
-2.46%
|
$5,199,283
$839.93 P/Share
|
|
Aug 23
2023
|
Daniel P Van Plew EVP & General Mgr, Industrial |
SELL
Payment of exercise price or tax liability
|
Direct |
16,928
-37.93%
|
$14,253,376
$842.66 P/Share
|
|
Aug 23
2023
|
Daniel P Van Plew EVP & General Mgr, Industrial |
BUY
Exercise of conversion of derivative security
|
Direct |
23,125
+34.13%
|
$8,810,625
$381.4 P/Share
|
|
Aug 23
2023
|
Christine A Poon Director |
SELL
Open market or private sale
|
Direct |
12,280
-26.61%
|
$10,302,920
$839.53 P/Share
|
|
Aug 23
2023
|
Christine A Poon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,280
+46.17%
|
$3,352,440
$273.67 P/Share
|
|
Aug 23
2023
|
Robert E Landry EVP Finance CFO |
SELL
Open market or private sale
|
Direct |
223
-0.7%
|
$188,212
$844.0 P/Share
|
|
Aug 23
2023
|
Christopher R. Fenimore SVP Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,198
-19.89%
|
$4,376,716
$842.66 P/Share
|
|
Aug 23
2023
|
Christopher R. Fenimore SVP Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+21.12%
|
$2,793,000
$399.66 P/Share
|
|
Aug 22
2023
|
Neil Stahl EVP Research and Development |
SELL
Open market or private sale
|
Direct |
11,665
-6.34%
|
$9,810,265
$841.37 P/Share
|
|
Aug 21
2023
|
Bonnie L Bassler Director |
SELL
Open market or private sale
|
Direct |
853
-40.62%
|
$707,137
$829.0 P/Share
|
|
Aug 21
2023
|
Bonnie L Bassler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
853
+28.89%
|
$333,523
$391.92 P/Share
|
|
Aug 21
2023
|
Neil Stahl EVP Research and Development |
SELL
Payment of exercise price or tax liability
|
Direct |
38,335
-37.18%
|
$31,933,055
$833.39 P/Share
|
|
Aug 21
2023
|
Neil Stahl EVP Research and Development |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+32.66%
|
$19,950,000
$399.66 P/Share
|
|
Aug 10
2023
|
Bonnie L Bassler Director |
SELL
Open market or private sale
|
Direct |
853
-40.62%
|
$673,017
$789.0 P/Share
|
|
Aug 10
2023
|
Bonnie L Bassler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
853
+28.89%
|
$333,523
$391.92 P/Share
|
|
Aug 01
2023
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.05%
|
$73,700
$737.75 P/Share
|
|
Aug 01
2023
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
250
-1.23%
|
$186,000
$744.66 P/Share
|
|
Jul 03
2023
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.05%
|
$71,500
$715.83 P/Share
|
|
Jul 03
2023
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
250
-1.22%
|
$177,500
$710.09 P/Share
|